KR102427844B1 - 세포 살상제 - Google Patents

세포 살상제 Download PDF

Info

Publication number
KR102427844B1
KR102427844B1 KR1020207004917A KR20207004917A KR102427844B1 KR 102427844 B1 KR102427844 B1 KR 102427844B1 KR 1020207004917 A KR1020207004917 A KR 1020207004917A KR 20207004917 A KR20207004917 A KR 20207004917A KR 102427844 B1 KR102427844 B1 KR 102427844B1
Authority
KR
South Korea
Prior art keywords
peptide
cngb3
leu ala
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004917A
Other languages
English (en)
Korean (ko)
Other versions
KR20200031670A (ko
Inventor
카즈히로 스기하라
나오히로 카나야마
유이치로 오노데라
토시아키 시바타
미치코 후쿠다
모토히로 노나카
Original Assignee
각코호진 후지타 가쿠엔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 각코호진 후지타 가쿠엔 filed Critical 각코호진 후지타 가쿠엔
Publication of KR20200031670A publication Critical patent/KR20200031670A/ko
Application granted granted Critical
Publication of KR102427844B1 publication Critical patent/KR102427844B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207004917A 2017-08-24 2018-08-23 세포 살상제 Active KR102427844B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2017-161556 2017-08-24
JP2017161556A JP6613499B2 (ja) 2017-08-24 2017-08-24 細胞殺傷剤
PCT/JP2018/031136 WO2019039540A1 (ja) 2017-08-24 2018-08-23 細胞殺傷剤

Publications (2)

Publication Number Publication Date
KR20200031670A KR20200031670A (ko) 2020-03-24
KR102427844B1 true KR102427844B1 (ko) 2022-07-29

Family

ID=65438932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004917A Active KR102427844B1 (ko) 2017-08-24 2018-08-23 세포 살상제

Country Status (9)

Country Link
US (2) US11357819B2 (enExample)
EP (1) EP3738601A4 (enExample)
JP (1) JP6613499B2 (enExample)
KR (1) KR102427844B1 (enExample)
CN (1) CN111065403B (enExample)
AU (1) AU2018322305B2 (enExample)
CA (1) CA3073392C (enExample)
SG (1) SG11202001484QA (enExample)
WO (1) WO2019039540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
WO2019138944A1 (ja) 2018-01-09 2019-07-18 学校法人藤田学園 細胞殺傷剤
JP2024517518A (ja) * 2021-05-07 2024-04-23 ツインピグ バイオラブ インコーポレイテッド マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用
CN115725968A (zh) * 2022-11-18 2023-03-03 东莞宜安科技股份有限公司 一种生物医用钛合金表面的复合涂层及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076501A2 (en) 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
WO2011027312A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS
WO2011079304A1 (en) * 2009-12-23 2011-06-30 Sanford-Burnham Medical Research Institute Methods and compositions related to annexin 1-binding compounds
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP2414389A1 (en) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides
EP3238782A3 (en) * 2010-04-06 2018-01-03 ExoCyte Therapeutics Pte, LTD Methods of treating cancer
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US10338068B2 (en) * 2013-07-08 2019-07-02 The Trustees Of Columbia University In The City Of New York Selection of biological objects
JPWO2015041019A1 (ja) * 2013-09-18 2017-03-02 国立大学法人京都大学 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
RU2571551C1 (ru) 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017161556A (ja) 2017-06-27 2017-09-14 パイオニア株式会社 位置認識装置、制御方法、プログラム、及び記憶媒体
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076501A2 (en) 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
WO2011027312A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS
WO2011079304A1 (en) * 2009-12-23 2011-06-30 Sanford-Burnham Medical Research Institute Methods and compositions related to annexin 1-binding compounds
WO2014201118A2 (en) * 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment

Also Published As

Publication number Publication date
CN111065403B (zh) 2023-09-26
AU2018322305B2 (en) 2021-05-20
CA3073392A1 (en) 2019-02-28
WO2019039540A1 (ja) 2019-02-28
JP2019038772A (ja) 2019-03-14
KR20200031670A (ko) 2020-03-24
JP6613499B2 (ja) 2019-12-04
CN111065403A (zh) 2020-04-24
SG11202001484QA (en) 2020-03-30
US20200289608A1 (en) 2020-09-17
EP3738601A4 (en) 2021-06-16
CA3073392C (en) 2023-02-21
EP3738601A1 (en) 2020-11-18
AU2018322305A1 (en) 2020-03-05
US20220280596A1 (en) 2022-09-08
US11357819B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
US20220280596A1 (en) Cytocidal agent
ES2909961T3 (es) Biomarcadores de células senescentes
CN109734777A (zh) 用于各种癌症免疫治疗的新型肽、肽组合物和支架
ES2728998T3 (es) Nuevo antígeno de cáncer EEF2
Yuan et al. The human milk-derived peptide drives rapid regulation of macrophage inflammation responses in the neonatal intestine
Kim et al. Clusterin interaction with Bcl-xL is associated with seizure-induced neuronal death
KR20130130562A (ko) 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도
CA3087744C (en) CYTOCIDAL AGENT
HK40023962A (zh) 细胞杀伤剂
WO2013163431A1 (en) Diagnosis and treatment of brain tumor
HK40032209A (en) Cytocide
Yuan et al. Targeted intracellular delivery of BH3 mimetic peptide inhibits BCL-2 activity and prevents breast cancer development
US20190030126A1 (en) Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
HK40032209B (en) Cytocide
HK40056363A (en) Peptide therapeutics for the treatment of cancer and uses thereof
HSP70 Department Chemie Lehrstuhl für Biotechnologie
Gausdal New lessons from an “old” drug: A proteomic study of anthracycline-induced apoptosis in acute myelogenous leukemia

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5